Empowering Community Oncologists in the New Era of Cancer Management: ADAPTATION OF THE IMMUNO-ONCOLOGY REGIONAL MEETING SERIES

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: May 07, 2015
Expiration Date: May 07, 2016

PracticalOncologist.com is pleased to offer the following continuing education activity Empowering Community Oncologists in the New Era of Cancer Management: Adaptation of the Immuno-Oncology Regional Meeting Series. This activity was previously presented as a series of live regional meetings that have been reaccredited and released for 4.5 hours of continuing medical, pharmacy or nursing education credit.

Please note:
If you previously attended and received credit at the live regional meeting, you are ineligible to receive additional credit for this enduring activity and may not re-submit for credits previously awarded.

Expected time to complete this activity as designed: 4.5 hours

There are no fees for participating in or receiving credit for this online activity.

Program Overview

The past decade has witnessed significant discoveries regarding the etiology and growth of various malignancies, with an explosion of information concerning biologic and/or genomic characteristics of a specific patient’s disease, allowing clinicians to tailor therapy for maximum effectiveness. As a result, with this growth of new science in immuno-oncology, guideline updates, and advances, the community hematologists/oncologists and associated multidisciplinary health care professionals will need to seek opportunities to obtain the most current information awareness and education in order to better understand and apply these new options in community practice.

Target Audience

This activity is designed for community oncologists and all other associated multidisciplinary health care professionals who have an interest in immunotherapy options.

Learning Objectives

At the conclusion of this educational activity, participants should be able to:

  • Identify and implement the various immunotherapeutic approaches that are available and undergoing clinical development for hematologic and solid tumors to improve patient outcomes (knowledge, competence, performance, patient outcomes);

  • Compare and contrast the mechanisms of action and pathways they target of various immunotherapeutics both available and those undergoing clinical investigation for hematologic and solid tumors (knowledge, competence);

  • Differentiate the responses to treatment and treatment-associated side effects of immunotherapies available and undergoing clinical development to those of conventional chemotherapeutics (knowledge, competence, performance);

  • Communicate with patients regarding the potential benefits of clinical trials and resources to assist in identifying those trials that are investigating immunotherapeutic strategies for hematologic and solid tumors that may be appropriate to individual cancer patient needs (knowledge, competence, performance).

Agenda

Module 1
The Principles of Tumor Immunology and Immunotherapy: Rationale for Immunotherapy – Jason J. Luke, MD, FACP

Module 2
Why Do Practitioners Need to Understand the Principles of Tumor Immunology and Immunotherapy in Today’s Practice? – Faculty Roundtable Discussion

Module 3
Current Status of Immunotherapy for Kidney, Prostate and Bladder Cancer – Bradley C. Carthon, MD, PhD

Module 4
Cancer Immunotherapy for Today: Advanced Melanoma – Jeffrey S. Weber, MD, PhD

Module 5
Integrating Available Immunotherapies into Practice: Monitoring and Evaluating Responses, Managing Treatment Associated Side Effects – Faculty Roundtable Discussion

Module 6
Immunotherapy in Cancer Patients – Jeffrey S. Weber, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through May 07, 2016. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Jason J. Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medical Center
Chicago, Illinois

Dr. Jason Luke received his medical degree from Rosalind Franklin University of Medicine and Science in Illinois. He completed an internship and residency at Boston University Medical Center, as well as fellowships in medicine at Weill Cornell Medical College and medical oncology at Memorial Sloan-Kettering Cancer Center. He is currently an assistant professor of medicine at The University of Chicago Medical Center where he helps create a comprehensive research program for melanoma and immunotherapeutics. Prior to coming to the University of Chicago, Dr. Luke was an instructor in medicine at the Dana-Farber Cancer Institute and Harvard Medical School where he treated patients with melanoma and performed early phase clinical trials.

Board certified in medicine and medical oncology, Dr. Luke holds memberships in the American Association for Cancer Research, American College of Physicians, American Medical Association, American Society of Clinical Oncology, Society for Immunotherapy of Cancer, and the Society for Melanoma Research. He has received advanced training in oncology drug development as a visiting physician at the National Cancer Institute (NCI), and has served on the melanoma science and education program committees for the American Society of Clinical Oncology (ASCO). In addition, Dr. Luke serves as the national study chair for the only ongoing national clinical trial for patients with advanced uveal (ocular) melanoma and is the principal investigator of several clinical trials of immunotherapy and targeted molecular therapies for melanoma and advanced cancer. His research, which has been supported by ASCO, the NCI and the National Comprehensive Cancer Network, focuses on translational therapeutic advances for melanoma and early phase drug development, particularly immunotherapy. In the context of a multidisciplinary team of doctors and nurses, Dr. Luke works to bring a personalized approach to each melanoma and advanced solid tumor patient through a comprehensive, compassionate, and individualized care plan that is at the forefront of medicine.

Bradley C. Carthon, MD, PhD
Assistant Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, Georgia

Dr. Bradley Carthon received his medical degree from Harvard Medical School in Boston, Massachusetts. He completed an internship and residency at Massachusetts General Hospital in Boston, and then went on to complete a fellowship at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Carthon is currently an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, Georgia.

Dr. Carthon is a member of the Discovery and Developmental Therapeutics Research Program. He works with the genitourinary oncology team at Winship Cancer Institute in order to discover novel therapeutic targets and carry out clinical trials that utilize novel treatment combinations for patients with prostate, bladder, and renal and other genitourinary malignancies.

Jeffrey S. Weber, MD, PhD
Director
Donald A. Adam Comprehensive Melanoma Research Center
Moffitt Cancer Center
Tampa, Florida

Dr. Jeffrey Weber received his medical degree from New York University Medical Center and his PhD in molecular cell biology from The Rockefeller University in New York City. He completed his residency and internship in medicine at the University of California, and his fellowships in medicine and tumor immunology at the National Cancer Institute. Dr. Weber is the director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center, where he is also a senior member. In addition, he is a professor of oncology and medicine at the University of South Florida College of Medicine.

Dr. Weber has served on the Melanoma Research Foundation scientific advisory committee and the scientific advisory board of the Melanoma Therapeutics Foundation. He has published more than 120 articles in peer reviewed journals. As a tumor immunologist and immunotherapist, Dr. Weber has an extensive history of conducting translational and investigator-initiated clinical trials, including development of novel trials in melanoma based on his lab work. His research interests are in monitoring and characterization of T-cell responses to vaccination in cancer patients, understanding how immune modulating antibodies amplify T-cell responses, and the mechanisms by which achieving autoimmunity induces regression of cancer. His main clinical interest involves immunotherapy for melanoma and other malignancies.

Accreditation

MediCom WOrldwide, Inc. CME CREDIT
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 4.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-014-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 4.5 contact hours. Program Number: 15-014-001

Disclosure

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

As an organization accredited by Accreditation Council for Continuing Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Faculty Disclosures

Dr. Bradley Carthon has disclosed no relevant financial relationships.

Dr. Jason Luke has received consultant fees from Amgen Inc., Bayer, AG, and Genentech, Inc. He has received grant support related to research activities from EMD Serono, Inc., GlaxoSmithKline plc, and Novartis AG.

Dr. Jeffrey Weber has received honoraria related to formal advisory activities and as a consultant from Bristol-Myers Squibb Company, GlaxoSmithKline, and Merck & Co., Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, Eugene R. Tombler, PhD, FACME, medical director, oncology, and William Stoff have no relevant financial relationships. Shirley Roy, MPH, University of Texas MD Anderson Cancer Center, has no relevant financial relationships. Larry W. Kwak, MD, PhD has received honoraria as a consultant from Biovest, Celltrion, OncoPep, and Xeme Biopharma and also has an ownership interest in Xeme Biopharma.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Carthon has indicated that he does not intend to discuss investigational or off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Luke and Dr. Weber have indicated that they do intend to discuss investigational or off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@practicaloncologist.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech, and Prometheus Therapeutics & Diagnostics

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.